source
- Pfizer’s monthly obesity drug berobenatide shows up to 12% weight loss in mid-stage VESPER-3 studyDetailed data from Pfizer's mid‑stage VESPER-3 trial indicate that the company’s monthly‑dosed obesity candidate, berobenatide, continues to demonstrate weight‑loss potential. The drug, originally…
- Former CDC director warns that new Ebola outbreak in DRC requires massive, immediate actionTom Frieden, who led the U.S. CDC response to the 2014‑2016 West Africa Ebola epidemic that killed more than 11,000 people, writes about the new crisis in the Democratic Republic of the Congo. He…